MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-05-2025
STAAR Surgical Company Balance Sheet 2011-2026 | STAA
Annual Balance Sheet STAAR Surgical Company
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-105 M | -179 M | -82.7 M | -196 M | -118 M | - | -99.6 M | -13.6 M | -9.04 M | -8.4 M | -18.1 M | - | -15.3 M | -12.9 M |
Long Term Debt |
34.8 M | 42 K | 210 K | 382 K | 366 K | - | 459 K | 531 K | 204 K | 468 K | 100 K | - | 500 K | 1.1 M |
Long Term Debt Current |
3.89 M | 4.2 M | 3.52 M | 3.28 M | 2.7 M | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 12.5 M | - | 7.18 M | 5.91 M | 6.22 M | 5.44 M | 4.7 M | - | 5.1 M | 5.5 M |
Total Current Liabilities |
70.3 M | 65 M | 51.7 M | 48.8 M | 34.5 M | - | 27.7 M | 19.1 M | 21.1 M | 16.4 M | 18.4 M | - | 17.9 M | 14 M |
Total Liabilities |
112 M | 103 M | 82.7 M | 87.2 M | 47 M | - | 34.9 M | 27.5 M | 24.1 M | 21.8 M | 23.1 M | - | 23 M | 19.5 M |
Deferred Revenue |
- | - | - | - | 3.75 M | - | 1.28 M | 1.24 M | 439 K | 596 K | 373 K | - | 187 K | 152 K |
Retained Earnings |
-67.6 M | -47.4 M | -68.7 M | -111 M | -142 M | - | -156 M | -161 M | -147 M | -140 M | -132 M | - | -132 M | -131 M |
Total Assets |
510 M | 489 M | 419 M | 346 M | 207 M | - | 167 M | 70.5 M | 63 M | 58.9 M | 61.9 M | - | 54.8 M | 49 M |
Cash and Cash Equivalents |
144 M | 183 M | 86.5 M | 200 M | 120 M | - | 104 M | 18.5 M | 14 M | 13 M | 23 M | - | 21.7 M | 16.6 M |
Book Value |
397 M | 386 M | 336 M | 259 M | 160 M | - | 132 M | 42.9 M | 38.8 M | 37.1 M | 38.8 M | - | 31.8 M | 29.5 M |
Total Shareholders Equity |
397 M | 386 M | 336 M | 262 M | 160 M | - | 132 M | 42.9 M | 37.9 M | 37.1 M | 38.9 M | - | 31.7 M | 29.5 M |
All numbers in USD currency
Quarterly Balance Sheet STAAR Surgical Company
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
33.8 M | 35.4 M | 33.1 M | 34.8 M | 35.4 M | 31.5 M | 31.1 M | 42 K | 84 K | 125 K | 167 K | 210 K | 252 K | 295 K | 338 K | 382 K | 21 K | 25 K | 28 K | 366 K | 73 K | 108 K | 132 K | - | 471 K | 580 K | 656 K | 459 K | 459 K | 459 K | 459 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
103 M | 101 M | 107 M | 112 M | 109 M | 104 M | 99.7 M | 103 M | 92.9 M | 87 M | 80 M | 82.7 M | 74.5 M | 76.7 M | 74.9 M | 87.2 M | 75.5 M | 59.8 M | 51.6 M | 47.6 M | 48.3 M | 43.4 M | 41.8 M | - | 43.4 M | 41.6 M | 39.9 M | 34.9 M | 34.9 M | 34.9 M | 34.9 M | 25 M | 27.5 M | 27.5 M | 27.5 M | 27.6 M | 27.5 M | 27.5 M | 27.5 M | 21.8 M | 22.4 M | 20.5 M | 20.5 M | 23.1 M | 22.2 M | 22.5 M | 23 M | - | 21.7 M | 20 M | 20 M | 23 M | 23 M | 23 M | 23 M | 19.5 M | 19.5 M | 19.5 M | 19.5 M |
Retained Earnings |
-130 M | -139 M | -122 M | -67.6 M | -33.3 M | -43.3 M | -50.7 M | -47.4 M | -55.1 M | -63.9 M | -69.9 M | -68.7 M | -78.5 M | -88.8 M | -102 M | -111 M | -116 M | -122 M | -131 M | -142 M | -139 M | -143 M | -142 M | - | -148 M | -151 M | -154 M | -156 M | -156 M | -156 M | -156 M | -161 M | -161 M | -161 M | -161 M | -159 M | -159 M | -159 M | -159 M | -140 M | -146 M | -144 M | -143 M | -132 M | -138 M | -135 M | -133 M | - | -131 M | -132 M | -132 M | -132 M | -132 M | -132 M | -132 M | -131 M | -131 M | -131 M | -131 M |
Total Assets |
456 M | 438 M | 457 M | 510 M | 538 M | 513 M | 493 M | 489 M | 472 M | 441 M | 419 M | 419 M | 395 M | 376 M | 351 M | 346 M | 325 M | 294 M | 266 M | 208 M | 235 M | 218 M | 207 M | - | 193 M | 186 M | 177 M | 167 M | 167 M | 167 M | 167 M | 67.9 M | 70.5 M | 70.5 M | 70.5 M | 65.5 M | 65.4 M | 65.4 M | 65.4 M | 58.9 M | 61.9 M | 60.3 M | 56.8 M | 61.9 M | 62.8 M | 64.4 M | 64.3 M | - | 59.5 M | 54.7 M | 52.7 M | 54.8 M | 54.8 M | 54.8 M | 54.8 M | 49 M | 49 M | 49 M | 49 M |
Cash and Cash Equivalents |
176 M | 167 M | 173 M | 144 M | 164 M | 193 M | 224 M | 183 M | 127 M | 94.7 M | 90 M | 86.5 M | 129 M | 202 M | 193 M | 200 M | 196 M | 173 M | 162 M | 120 M | 128 M | 116 M | 111 M | - | 112 M | 103 M | 102 M | 104 M | 104 M | 104 M | 104 M | 18.5 M | 18.5 M | 18.5 M | 18.5 M | 14 M | 14 M | 14 M | 14 M | 13 M | 16.1 M | 15.3 M | 10.8 M | 23 M | 18.4 M | 19.2 M | 21.1 M | - | 23.4 M | 19.7 M | 19.2 M | 21.7 M | 21.7 M | 21.7 M | 21.7 M | 16.6 M | 16.6 M | 16.6 M | 16.6 M |
Book Value |
354 M | 337 M | 350 M | 397 M | 428 M | 409 M | 393 M | 386 M | 379 M | 354 M | 339 M | 336 M | 320 M | 299 M | 276 M | 259 M | 249 M | 235 M | 214 M | 160 M | 186 M | 175 M | 165 M | - | 149 M | 144 M | 137 M | 132 M | 132 M | 132 M | 132 M | 42.9 M | 42.9 M | 42.9 M | 42.9 M | 37.9 M | 37.9 M | 37.9 M | 37.9 M | 37.1 M | 39.5 M | 39.8 M | 36.3 M | 38.9 M | 40.6 M | 41.8 M | 41.3 M | - | 37.8 M | 34.7 M | 32.6 M | 31.7 M | 31.7 M | 31.7 M | 31.7 M | 29.5 M | 29.5 M | 29.5 M | 29.5 M |
Total Shareholders Equity |
354 M | 337 M | 350 M | 397 M | 428 M | 409 M | 393 M | 386 M | 379 M | 358 M | 343 M | 336 M | 323 M | 299 M | 276 M | 259 M | 249 M | 235 M | 214 M | 160 M | 186 M | 175 M | 165 M | - | 149 M | 144 M | 137 M | 132 M | 132 M | 132 M | 132 M | 42.9 M | 42.9 M | 42.9 M | 42.9 M | 37.9 M | 37.9 M | 37.9 M | 37.9 M | 37.1 M | 39.5 M | 39.8 M | 36.3 M | 38.9 M | 40.6 M | 41.8 M | 41.3 M | - | 37.8 M | 34.7 M | 32.6 M | 31.7 M | 31.7 M | 31.7 M | 31.7 M | 29.5 M | 29.5 M | 29.5 M | 29.5 M |
All numbers in USD currency
Balance Sheet is a fundamental financial report of STAAR Surgical Company, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Medical instruments
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Atrion Corporation
ATRI
|
- | - | $ 810 M |  USA |
 |
Baxter International
BAX
|
$ 19.11 | -0.98 % | $ 9.75 B | USA |
 |
Becton, Dickinson and Company
BDX
|
$ 194.07 | -0.8 % | $ 55.8 B | USA |
 |
Luminex Corporation
LMNX
|
- | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
- | -9.52 % | $ 20.6 M | USA |
 |
Ekso Bionics Holdings
EKSO
|
$ 8.64 | -18.34 % | $ 174 M | USA |
 |
Antares Pharma, Inc.
ATRS
|
- | - | $ 955 M | USA |
 |
Cantel Medical Corp.
CMD
|
- | -1.18 % | $ 3.4 B | USA |
 |
CRH Medical Corporation
CRHM
|
- | - | $ 282 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
- | -0.05 % | $ 10.3 B | USA |
 |
Harvard Bioscience
HBIO
|
$ 0.67 | 1.66 % | $ 28.4 M | USA |
 |
Varian Medical Systems, Inc.
VAR
|
- | -0.02 % | $ 16.3 B | USA |
 |
Alcon
ALC
|
$ 78.81 | -0.64 % | $ 40.4 B |  Schweiz |
 |
Repro Med Systems
KRMD
|
$ 5.81 | 2.11 % | $ 265 M | USA |
 |
AtriCure
ATRC
|
$ 39.56 | -1.54 % | $ 1.86 B | USA |
 |
ICU Medical
ICUI
|
$ 142.67 | -1.36 % | $ 3.48 B | USA |
 |
electroCore
ECOR
|
$ 4.49 | -3.55 % | $ 24.8 K | USA |
 |
iRhythm Technologies
IRTC
|
$ 177.44 | -0.63 % | $ 5.54 B | USA |
 |
AngioDynamics
ANGO
|
$ 12.84 | -1.23 % | $ 525 M | USA |
 |
Isoray
ISR
|
- | 0.03 % | $ 108 M | USA |
 |
The Cooper Companies
COO
|
$ 81.96 | -0.62 % | $ 16.3 B | USA |
 |
Glaukos Corporation
GKOS
|
$ 112.91 | -1.16 % | $ 5.47 B | USA |
 |
LeMaitre Vascular
LMAT
|
$ 81.1 | -2.3 % | $ 1.82 B | USA |
 |
Haemonetics Corporation
HAE
|
$ 80.15 | -1.02 % | $ 4.03 B | USA |
 |
InfuSystem Holdings
INFU
|
$ 8.97 | 0.67 % | $ 185 M | USA |
 |
Nephros
NEPH
|
$ 4.88 | 3.39 % | $ 50.7 M | USA |
 |
Masimo Corporation
MASI
|
$ 130.06 | -0.77 % | $ 6.93 B | USA |
 |
Merit Medical Systems
MMSI
|
$ 88.14 | -0.47 % | $ 5.13 B | USA |
 |
Intuitive Surgical
ISRG
|
$ 566.36 | -1.09 % | $ 201 B | USA |
 |
OraSure Technologies
OSUR
|
$ 2.42 | -2.02 % | $ 180 M | USA |
 |
Microbot Medical
MBOT
|
$ 2.0 | -2.44 % | $ 20.4 M |  Israel |
 |
Milestone Scientific
MLSS
|
$ 0.27 | -0.22 % | $ 21.5 M | USA |
 |
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | USA |
 |
Envista Holdings Corporation
NVST
|
$ 21.71 | -0.91 % | $ 3.74 B | USA |
 |
Pro-Dex
PDEX
|
$ 38.48 | -0.3 % | $ 127 M | USA |
 |
Predictive Oncology
POAI
|
- | - | $ 32.4 M | USA |
 |
Pulse Biosciences
PLSE
|
$ 13.73 | 0.22 % | $ 660 M | USA |
 |
ResMed
RMD
|
$ 240.87 | -0.91 % | $ 35.2 B | USA |
 |
Repligen Corporation
RGEN
|
$ 163.86 | -1.64 % | $ 9.13 M | USA |
 |
BioLife Solutions
BLFS
|
$ 24.18 | -1.95 % | $ 1.11 B | USA |
 |
STERIS plc
STE
|
$ 253.52 | -0.76 % | $ 25 B | USA |
 |
Stereotaxis
STXS
|
$ 2.3 | -0.22 % | $ 186 M | USA |
 |
Retractable Technologies
RVP
|
$ 0.77 | -0.63 % | $ 23.1 M | USA |
 |
Utah Medical Products
UTMD
|
$ 55.96 | -0.57 % | $ 203 M | USA |
 |
Teleflex Incorporated
TFX
|
$ 122.04 | 0.35 % | $ 5.72 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
$ 11.43 | 0.35 % | $ 2.32 B | USA |
 |
West Pharmaceutical Services
WST
|
$ 275.14 | -0.62 % | $ 20.1 B | USA |